Key result
Age over 65 years was a significant prognostic factor for median overall survival (p=0.015) in patients with synovial sarcoma, who had an overall median survival of 96.7 months.
Why the study?
Synovial sarcomas have a high tendency for local relapse and metastases despite complete surgical excision, prompting analysis of clinical presentation, treatment course, outcomes, and prognosis.
Cohort (n=134)
No
p-value: p=0.015
In a retrospective cohort of 134 patients with synovial sarcoma, median overall survival was 96.7 months, with age over 65 identified as a significant negative prognostic factor.
Age >65 associated with shorter survival in synovial sarcoma; leaves open prospective validation of this prognostic factor.
BACKGROUND: Synovial sarcomas (SS) are malignant mesenchymal neoplasms that account for about 10% of all sarcomas. Complete surgical excision is the mainstay of primary treatment for localized disease, but SS have a high tendency for local relapse and metastases. Metastatic disease is commonly treated with systemic chemotherapy. METHODS: We designed a retrospective analysis to describe the clinical presentation, course of treatment, outcome, and prognosis of patients with SS. Univariate and multivariate analyses were performed for potential prognostic factors. RESULTS: We identified 134 patients treated between 1987 and 2018, with a cutoff date of December 2018. Demographics, disease characteristics, treatment, and survival rates were collected and analyzed. The median overall survival (mOS) from the date of diagnosis was 96.7 months. The median progression-free survival was 6.37 months. Disease-free survival was 26 months. Age over 65 years was found to be a prognostic factor with statistically significant value in the univariate analysis regarding mOS (p = 0.015) and mOS after local relapse (p = 0.0228). CONCLUSIONS: Even though our study is limited by the retrospective nature of the analysis, it adds an important amount of clinical data regarding the treatment and outcome of SS.
No takes yet. Share an insight, caveat, or question.
Kyriazoglou et al. (2021) conducted a cohort in Synovial Sarcoma (n=134). Age over 65 years vs. Age 65 years or younger was evaluated on Median overall survival (p=0.015). Age over 65 years was a significant prognostic factor for median overall survival (p=0.015) in patients with synovial sarcoma, who had an overall median survival of 96.7 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: